Previous 10 | Next 10 |
Adial to focus on late-stage clinical development for AD04 for alcohol use disorder; potential sale of Purnovate to new company formed by former Adial CEO and current Purnovate CEO, William Stilley Potential development/commercial milestone payments of up to $83 million on first three com...
Adial Pharmaceuticals press release ( NASDAQ: ADIL ): Q3 GAAP EPS of -$0.12 beats by $0.06 . As of September 30, 2022, cash and cash equivalents were $5.8 million as compared to $6.1 million as of December 31, 2021. For further details see: Adial Pharmaceutic...
Advancing submission of AD04 ONWARD™ phase 3 results to regulatory agencies Actively exploring potential partnership opportunities for AD04 and Purnovate compounds Promoted Cary Claiborne to President and Chief Executive Officer CHARLOTTESVILLE, Va., Nov. 14, 2022 (...
CHARLOTTESVILLE, Va., Sept. 26, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine re...
CHARLOTTESVILLE, Va., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW) (“Adial” or the “Company”), today announced that Purnovate, Inc., a subsidiary of Adial focused on developing novel molecules targeting the adenosine re...
Adial Pharmaceuticals ( NASDAQ: ADIL ) appoints Cary J. Claiborne as President and CEO. Mr. Claiborne takes over the role of William Stilley, who was appointed to the newly created position of CEO of Purnovate. Both executives will remain ...
Kevin Schuyler appointed Chairman of Adial’s Board William Stilley moves to post of CEO of Adial’s subsidiary, Purnovate Company to host conference call at 8:30 a.m. EDT tomorrow CHARLOTTESVILLE, Va., Aug. 22, 2022 (GLOBE NEWSWIRE) -- Adial Pharmace...
Onward Phase III Clinical Trial of Adial Pharmaceutical’s AD04, a treatment for Alcohol Abuse Disorder, was completed in early 2022. A subset of study participants, the Heavy Drinker group, demonstrated clear benefit from AD04 with a 79% reduction in heavy drinking days, the pr...
Adial Pharmaceuticals ( NASDAQ: ADIL ) stock fell ~3% on Aug. 17 after Maxim downgraded the stock to Hold from Buy citing need for capital after a trial of Alcohol Use Disorder (AUD) drug AD04 missed its main goal last month. The SA Quant Rating on ADIL is Sell ...
Adial Pharmaceuticals press release ( NASDAQ: ADIL ): Q2 GAAP EPS of -$0.16 beats by $0.01 . As of June 30,2022, cash and cash equivalents were $9.2 million as compared to $6.1 million as of December 31, 2021, which the Company believes provides sufficient runway to ad...
News, Short Squeeze, Breakout and More Instantly...
Adial Pharmaceuticals Inc Company Name:
ADIL Stock Symbol:
NASDAQ Market:
Adial Pharmaceuticals Inc Website:
GLEN ALLEN, Va., June 20, 2024 (GLOBE NEWSWIRE) -- Adial Pharmaceuticals, Inc. (NASDAQ: ADIL) (“Adial” or the “Company”), a clinical-stage biopharmaceutical company focused on developing therapies for the treatment and prevention of addiction and related disorders,...
NEW YORK, NY / ACCESSWIRE / June 6, 2024 / Today the MicroCap Rodeo - Spring into Summer will take place in-person on Thursday, June 6th, 2024 and host the executive management teams of 25 microcap companies. The conference will be held live at Convene NYC, with company presentations from begin...